{
    "clinical_study": {
        "@rank": "164760", 
        "acronym": "SpineSurgery", 
        "arm_group": [
            {
                "arm_group_label": "Spine surgery", 
                "description": "Patients undergoing spine surgery"
            }, 
            {
                "arm_group_label": "Bone surgery", 
                "description": "Patients undergoing bone surgery for fracture treatment other than spine fractures"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum levels of the biomarkers S-100B and NSE are measured"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The hypothesis of this study is to find evidence if there is an influence of spine surgery\n      on the serum levels of two proteins secreted from neuronal cells."
        }, 
        "brief_title": "Neuromarker S-100B as Diagnostic Tool", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Spinal Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The question, if there is an effect on the cerebrospinal system during spine surgery, which\n      can be traced by monitoring serum levels of neuromarkers is not yet answered. This study has\n      its background from other studies on patients with traumatic brain injury (TBI), in whom\n      elevated serum levels of the two neuromarkers S-100B and NSE are associated with injury\n      severity, neuronal damage, brain, tissue damage, and outcome. Patients undergoing spine\n      surgery with or without pre-existing traumatic neurologic symptoms are planned to be the\n      study cohort. Pre- and postoperatively the serum levels of S-100B and NSE are obtained and\n      are statistically compared with patients undergoing other types of bone-related surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  spine fracture\n\n        Exclusion Criteria:\n\n          -  additional traumatic brain injury\n\n          -  fractures of the long bones\n\n          -  polytrauma\n\n          -  severely injured patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with spine fractures undergoing spine surgery for fracture stabilization"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840397", 
            "org_study_id": "Wolf-6"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "S-100B", 
            "NSE"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "A-1090"
                }, 
                "name": "Medical University of Vienna"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_groups": "2", 
        "official_title": "Elevated Levels of S-100B and Neuron-specific Enolase (NSE) in Spine Surgery: A Comparison of Serum Levels With Surgery for Long-bone Fractures", 
        "overall_official": {
            "affiliation": "Medical University of Vienna, Department for Trauma Surgery", 
            "last_name": "Harald Wolf, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "average timeframe between blood withdrawal (twice, pre-and post-operatively)", 
            "measure": "S-100B levels", 
            "safety_issue": "No", 
            "time_frame": "4 hours"
        }, 
        "reference": [
            {
                "PMID": "18343116", 
                "citation": "Cao F, Yang XF, Liu WG, Hu WW, Li G, Zheng XJ, Shen F, Zhao XQ, Lv ST. Elevation of neuron-specific enolase and S-100beta protein level in experimental acute spinal cord injury. J Clin Neurosci. 2008 May;15(5):541-4. doi: 10.1016/j.jocn.2007.05.014. Epub 2008 Mar 14."
            }, 
            {
                "PMID": "21535942", 
                "citation": "Marquardt G, Setzer M, Theisen A, Tews DS, Seifert V. Experimental subacute spinal cord compression: correlation of serial S100B and NSE serum measurements, histopathological changes, and outcome. Neurol Res. 2011 May;33(4):421-6. doi: 10.1179/1743132810Y.0000000005."
            }, 
            {
                "PMID": "19040802", 
                "citation": "Marquardt G, Setzer M, Szelenyi A, Seifert V, Gerlach R. Prognostic relevance of serial S100b and NSE serum measurements in patients with spinal intradural lesions. Neurol Res. 2009 Apr;31(3):265-9. doi: 10.1179/174313209X382287. Epub 2008 Nov 26."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840397"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Harald Wolf, MD", 
            "investigator_title": "Dr. Harald Wolf", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}